Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Five Prime Therapeutics

Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN) announced a $1.9 billion buyout of Five Prime Therapeutics Inc (NASDAQ: FPRX) that outlasted around 15 potential collaborators. Background: Amgen's interest in FPRX goes back to 2019 when it, alongside others (not named in the SEC filing), tried to bet on FPRX's pipeline.

Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors

Amgen rewarded investors by producing a five-year CAGR of 10.2% in total returns and 15.2% in dividend increases. Biosimilars' threat has been converted into a business opportunity by becoming a dominant player in the biosimilars market.

Amgen: Powerful Growth Platform Built To Reward Dividend Growth Investors

Applied Materials

Lam Research

Qorvo

With the first quarter soon coming to an end, many investors are looking to print some solid gains for the first three months of 2021, while turning their attention to what could be a very strong second quarter for the economy and for stocks.

Goldman Sachs Has 4 Tech and Biotech Stocks to Buy With Big-Time Growth Potential

Amgen, Inc. (AMGN) Presents at Oppenheimer Healthcare Broker Conference Call - (Transcript)

It's not getting much attention lately, but the future for Amgen looks strong.

Why the Growth Isn't Over for This Best-in-Breed Biotech Stock

THOUSAND OAKS, Calif., March 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m.

Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference

Adaptive Biotechnologies

BioNTech SE

Illumina

Moderna

Microsoft

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.

Why You Should Own Biotech Stocks Now

Amgen has come back down from a period of slight capital appreciation which saw the company's forward expected returns deteriorate to levels I found unappealing.

Amgen: 10-12% Upside Going Into March

Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.

Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout

Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.

ETFs to Tap Amgen's Drive for Cancer Deal

Amgen Inc. (AMGN) Management Presents at Cowen 41st Annual Healthcare Conference (Transcript)

The stock price of Five Prime Therapeutics Inc (NASDAQ: FPRX) increased by 78.74% today. This is why it happened.

FPRX Stock Price Increases 78.74% On Amgen Acquisition News

Amgen is an American biopharmaceutical company focusing especially on diseases in the field of oncology and hematology, inflammation or cardiovascular.

Amgen: One Of The Few Bargains In This Market

The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.

Amgen to Buy Oncology Start-Up Five Prime Therapeutics for $1.9 Billion

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Down 5.5% Since Last Earnings Report: Can It Rebound?

Amgen is paying a premium to buy the small biotech.

Why Five Prime Therapeutics Stock Is Skyrocketing Today

Five Prime Therapeutics (FPRX) stock is soaring higher on Thursday following news that Amgen (AMGN) is acquiring the company. The post FPRX Stock: The Huge Takeover News That Has Five Prime Therapeutics Shares Blasting Higher appeared first on InvestorPlace.

FPRX Stock: The Huge Takeover News That Has Five Prime Therapeutics Shares Blasting Higher

Amgen Inc (NASDAQ: AMGN) has agreed to acquire Five Prime Therapeutics Inc (NASDAQ: FPRX) for $38 per share in cash, representing an equity value of approximately $1.9 billion. The offer price of $38 represents a whopping 79% premium on the last close price of $21.26 on Wednesday.

Amgen Pays $1.9B For Five Prime Therapeutics Acquisition

Amgen said Thursday it will spend $1.9 billion to buy Five Prime Therapeutics, a small biotech company with a promising stomach cancer drug. The news sent FPRX stock rocketing.

Five Prime Therapeutics Stock Rockets On Amgen's $1.9 Billion Takeover

Amgen Inc. announced Thursday an agreement to buy biotechnology company Five Prime Therapeutics Inc. in a cash deal valued at $1.9 billion. Five Prime shares were halted for news until 9 a.m.

Amgen to buy Five Prime Therapeutics in a deal valued at $1.9 billion to boost cancer treatment portfolio

THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash

THOUSAND OAKS, Calif., March 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021, to all stockholders of record as of the close of business on...

Amgen Announces 2021 Second Quarter Dividend

AstraZeneca

AstraZeneca Plc (NASDAQ: AZN) and its partner Amgen Inc (NASDAQ: AMGN) have announced positive results from NAVIGATOR Phase 3 trial evaluating tezepelumab in severe asthma. Results were presented at the American Academy of Asthma Allergy & Immunology Annual Meeting.

AstraZeneca/Amgen's Tezepelumab Reduces Asthma Exacerbations, Phase 3 Trial Shows

THOUSAND OAKS, Calif., Feb. 26, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma. When added to standard of...

Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma

THOUSAND OAKS, Calif., Feb. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021. Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive...

News for Amgen Stock (AMGN)